Cationic liposomes delivered with tumor vaccines and IDO inhibitors provide a promising platform for cancer immunotherapy by provoking antitumor T-cell immunity and reversing the immunosuppressive tumor microenvironment (218). This evidence concerns the gene IDO1 and neoplasm.